For the fiscal year 2023, the company expects ZTALMY U.S. net product revenues of between $15 million and $17 million, BARDA revenues in the range of $8 million to $11 million and total GAAP operating expenses, inclusive of SG&A and R&D, to be in the range of $165 to $175 million, of which the company expects stock-based compensation to be approximately $16 million.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRNS:
- Marinus Pharmaceuticals options imply 12.7% move in share price post-earnings
- Billionaire Steve Cohen Pulls the Trigger on These 2 ‘Strong Buy’ Stocks
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Marinus Pharmaceuticals initiated with an Outperform at RBC Capital
- Marinus Pharmaceuticals management to meet with Cantor Fitzgerald
